NECTIN1 and posterior cortical atrophy: Our objectives were dual‐fold: first, to establish a preclinical rationale for utilizing EV in metastatic PCa, and second, to explore the NECTIN‐4 expression across different stages of the disease in order to identify subgroups who most likely benefit from EV treatment.